29 Result(s)

Article

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Monoclonal antibodies (mAbs) are a recent addition to multiple myeloma (MM) therapies and a number of mAbs directed at myeloma cell surface molecules are in development. Daratumumab is a CD38 mAb that has demo...

Philippe Moreau, Niels W. C. J. van de Donk, Jesus San Miguel, Henk Lokhorst… in Drugs (2016)

Article

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Philippe Moreau, Niels W. C. J. van de Donk, Jesus San Miguel, Henk Lokhorst… in Drugs (2016)

Article

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial

Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections and study risk factors f...

Charles Dumontet, Cyrille Hulin, Meletios A. Dimopoulos, Andrew Belch… in Leukemia (2018)

Article

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining and repair. This study defines incidence of ...

Maria Chiara Fontana, Giovanni Marconi, Jelena D. Milosevic Feenstra… in Leukemia (2018)

Article

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ ...

Heinz Ludwig, Michel Delforge, Thierry Facon, Hermann Einsele, Francesca Gay… in Leukemia (2018)

Article

Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

Laurent Garderet, Jacob P. Laubach, Anne-Marie Stoppa, Parameswaran Hari… in Leukemia (2018)

Article

Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study

Umbilical Cord Blood (UCB) represents a valid option for patients with hematopoietic malignancies lacking an HLA matched donor. To overcome the limitation of the low stem cell dose of UCB, the intrabone (IB) r...

Francesca Bonifazi, Elisa Dan, Myriam Labopin… in Bone Marrow Transplantation (2019)

Article

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and len...

Matilde Y. Follo, Andrea Pellagatti, Richard N. Armstrong, Stefano Ratti… in Leukemia (2019)

Article

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention...

C. Ola Landgren, Ajai Chari, Yael C. Cohen, Andrew Spencer, Peter Voorhees… in Leukemia (2020)

Article

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), wit...

Hartmut Goldschmidt, Meletios A. Dimopoulos, S. Vincent Rajkumar… in Leukemia (2020)

Article

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis

The phase 3 ALCYONE study demonstrated significantly longer progression-free and overall survival (PFS/OS) and higher overall response rates (ORR) with daratumumab plus bortezomib, melphalan, and prednisone (D...

Vania Hungria, Deborah M. Martínez-Baños, María-Victoria Mateos… in Advances in Therapy (2020)

Article

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased ris...

Heinz Ludwig, Mario Boccadoro, Philippe Moreau, Jesus San-Miguel, Michele Cavo… in Leukemia (2021)

Article

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

Daratumumab is a CD38-targeting monoclonal antibody that has demonstrated clinical benefit for multiple myeloma. Daratumumab inhibition of CD38, which is expressed on immune cell populations and cardiomyocytes...

Ajai Chari, Markus Munder, Katja Weisel, Matthew Jenner… in Advances in Therapy (2021)